RT Journal Article
T1 Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers.
A1 Novelli, Silvana
A1 Bento, Leyre
A1 Garcia, Irene
A1 Prieto, Laura
A1 Lopez, Lucia
A1 Gutierrez, Gonzalo
A1 Hernani, Rafael
A1 Perez, Ariadna
A1 Esquirol, Albert
A1 Solano, Carlos
A1 Bastos, Mariana
A1 Dorado, Nieves
A1 Rodriguez, Nancy
A1 Rodriguez, Guillermo
A1 Piñana, Jose L
A1 Montoro, Juan
A1 Herrera, Pilar
A1 Luna, Alejandro
A1 Parody, Rocio
A1 Martín, Carmen
A1 Garcia, Estefania
A1 Lopez, Oriana
A1 Heras, Inmaculada
A1 Zanabili, Joud
A1 Moraleda, Jose M
A1 Yañez, Lucrecia
A1 Gutierrez, Antonio
A1 Zudaire, Teresa
A1 Cordoba, Raul
A1 Varela, Rosario
A1 Ferra, Christelle
A1 Martinez, Joaquin
A1 Martinez, Carmen
A1 Gonzalez-Barca, Eva
A1 Martino, Rodrigo
A1 Caballero, Dolores
K1 Allogeneic stem cell transplantation
K1 Haploidentical
K1 T cell lymphoma
AB Despite advances in understanding the biology of mature T and natural killer (NK)/T cell neoplasia, current therapies, even the most innovative ones, are still far from ensuring its cure. The only treatment to date that has been shown to control aggressive T cell neoplasms in the long term is allogeneic stem cell transplantation (alloSCT). We aim to report the results of alloSCT for advanced mature T and NK/T neoplasias performed in centers from our national GELTAMO/GETH (Grupo Español de Linfoma y Trasplante de Médula Ósea/Grupo Español de Trasplante Hematopoyético y Terapia Celular) over the past 25 years. As a secondary objective, we analyzed the results of alloSCT from haploidentical donors. We performed a retrospective analysis of all patients who received an alloSCT in Spanish centers (n = 201) from September 1995 to August 2018. The 2-year overall survival (OS) and disease-free survival (DFS) were 65.5% and 58.2%, respectively. The univariate for OS and DFS showed statistically different hazard ratios for conditioning intensity, response pre-alloSCT, comorbidity index, donor/receptor cytomegalovirus status and Eastern Cooperative Oncology Group (ECOG) pre-alloSCT, but only a better ECOG pre-alloSCT remained significant in the multivariate analysis. There was an increased incidence of relapse in those patients who did not develop chronic graft-versus-host disease (GVHD) and an increased risk of death in those developing moderate to severe acute GVHD. The 1-year nonrelapse mortality was 21.9% and was mainly due to GVHD (30%) and bacterial infections (17%). When comparing unrelated donors with haploidentical donors, we found similar results in terms of OS and DFS. There was, however, a reduction of acute GVHD in the haploidentical group (P = .04) and trend to a reduction of chronic GVHD. In conclusion, alloSCT is the only curative option for most aggressive T cell neoplasias. Haploidentical donors offer similar results to related donors in terms of survival with a reduction of acute GVHD.
PB Elsevier Inc.
YR 2021
FD 2021-03-15
LK http://hdl.handle.net/10668/17585
UL http://hdl.handle.net/10668/17585
LA en
NO Novelli S, Bento L, Garcia I, Prieto L, López L, Gutierrez G, et al. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers. Transplant Cell Ther. 2021 Jun;27(6):493.e1-493.e8.
DS RISalud
RD Apr 9, 2025